This could be achieved by crossing the FLAG-Trp53 mice with transgenic mice expressing an oncogene, such as c-Myc, in which mutations in Trp53 are prevalent cooperating oncogenic lesions driving tumorigenesis, selecting those lymphomas that have sustained a mutation of interest in the FLAG-Trp53 allele. This evidence concerns the gene MYC and lymphoma.